Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00501
|
|||||
| Drug Name |
Desipramine
|
|||||
| Synonyms |
(3-(10H,11H-Dibenzo[b,f]azepin-5-yl)propyl)methylamine; 10, 11-Dihydro-N-methyl-5H-dibez[b,f]azepine-5-propanamine; 10,11-Dihydro-5-(3-methylaminopropyl)-5H-dibenz(b,f)azepine; 3-(10,11-DIHYDRO-5H-DIBENZO[B,F]AZEPIN-5-YL)-N-METHYLPROPAN-1-AMINE; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine; 5-(gamma-Methylaminopropyl)iminodibenzyl; DMI (pharmaceutical); DMI 50475; Demethylimipramine; Desimipramine; Desimpramine; Desipramin; Desipramina; Desipramina [INN-Spanish]; Desipramine (D4); Desipramine (INN); Desipramine Hcl; Desipramine [INN:BAN]; Desipraminum; Desipraminum [INN-Latin]; Desmethylimipramine; Dezipramine; Dimethylimipramine; Methylaminopropyliminodibenzyl; Monodemethylimipramine; N-(3-Methylaminopropyl)iminobibenzyl; Norimipramine; Norpramin (TN); Norpramine; Pentofran; Pertofrane (TN); Pertrofane; Sertofran; ZERO/006017
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Attention deficit hyperactivity disorder [ICD11: 6A05] | Approved | [1] | |||
| Depression [ICD11: 6A8Z] | Approved | [1] | ||||
| Therapeutic Class |
Antidepressants
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C18H22N2
|
|||||
| Canonical SMILES |
CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31
|
|||||
| InChI |
InChI=1S/C18H22N2/c1-19-13-6-14-20-17-9-4-2-7-15(17)11-12-16-8-3-5-10-18(16)20/h2-5,7-10,19H,6,11-14H2,1H3
|
|||||
| InChIKey |
HCYAFALTSJYZDH-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 50-47-5
|
|||||
| Pharmaceutical Properties | Molecular Weight | 266.4 | Topological Polar Surface Area | 15.3 | ||
| Heavy Atom Count | 20 | Rotatable Bond Count | 4 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 2 | |||
| XLogP |
4.9
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10524411
, 11111066
, 11111067
, 11335365
, 11360604
, 11363335
, 11365897
, 11368459
, 11371457
, 11374067
, 11376621
, 11461576
, 11466371
, 11467491
, 11483778
, 11486062
, 11487907
, 11490195
, 11492129
, 11494255
, 14774838
, 29214812
, 29222144
, 3249345
, 3727070
, 46504624
, 47291013
, 47291014
, 47736341
, 47736342
, 47736343
, 47959596
, 48259094
, 48259095
, 48415856
, 49698852
, 49961473
, 50100220
, 50104283
, 5321893
, 53787179
, 57321547
, 647048
, 76076257
, 7737258
, 7979043
, 8151907
, 85209781
, 85753308
, 9158
|
|||||
| ChEBI ID |
ChEBI:47781
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | OCT-1 | Transporter Info | Organic cation transporter 1 | Substrate | [2] | |
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
| References | ||||||
| 1 | Desipramine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33. | |||||
| 3 | A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.